The Food and Drug Administration on Tuesday approved donanemab for treating Alzheimer’s disease, after clinical studies indicated Eli Lilly’s drug could significantly slow cognitive decline, following years of delays to get the experimental treatment to market.
The monthly injection showed "very meaningful results" in slowly cognitive decline, the company ... [+]
Eli Lilly’s donanemab—to be sold under the brand name Kisunla—received regulatory approval as a monthly injection after an 18-month trial showed “very meaningful results” in slowing cognitive and functional decline in patients with Alzheimer’s, the company said.
This is a developing story and will be updated.
Get Forbes Breaking News Text Alerts: We’re launching text message alerts so you'll always know the biggest stories shaping the day’s headlines. Text “Alerts” to (201) 335-0739 or sign up here.